According to a report published in the British medical journal, The Lancet, the COVID-19 vaccine produced a dual immune response in people aged 18 to 55.
Officially known as AZD1222, this COVID-19 vaccine candidate has been developed by the University of Oxford and British-Swedish pharmaceutical company AstraZeneca Plc.
AstraZeneca has joined Serum Institute of India (SII), the world’s largest vaccine manufacturers by number of doses produced and sold, to produce the potential vaccine.
Serum Institute will produce 3 to 4 million doses of Oxford’s COVID-19 vaccine this year, Poonawalla said. “… we are hoping to get approvals in about two weeks. After that, we will begin phase 3 human trials here in India,” Adar Poonawalla, the chief executive officer of Serum Institute of India, said.
The company has already manufactured around 2-3 million doses of the vaccine for getting the process correct and also stabilising its machinery, Ponnawalla said.
In addition to manufacturing the Oxford vaccine, Serum Institute may take up additional manufacturing of COVID-19 vaccines developed by other entities.
When asked about the tentative prince range of the COVID-19 vaccine, Adar said that it may be too soon to comment, but they want to make the vaccine really affordable as they “don’t want to make a profit out of the pandemic.”